Director, RaaS Research Group, Research as a Service (RaaS)

RaaS Research Group (RaaS)

Director, RaaS Research Group

Insightful Financial Models and Research Analysis

Research as a Service (RaaS)

Connect to the right investors through smart and insightful financial models and research analysis.

Equity Bottom-Up

<div>
<div>
<div>
<div>
<p>Alcidion (ASX:ALC) was founded in Adelaide in 2000 with the aim of driving meaningful change in health outcomes with smart technology and joined the ASX in January 2016. ALC aims to deliver value to existing patient and clinician information systems by aggregating the data available in healthcare systems, centralising it in the company’s Miya Precision platform, and using that data to support health professionals in their clinical decision- making. ALC has expanded organically and by acquisition into the Australian, New Zealand and UK markets with a significant step-up in the UK since acquiring MKM Health in 2018. ALC went on to acquire Silverlink in December 2021 funded by a $55m capital raising. Silverlink is a Patient Administration System (PAS) provider serving the UK NHS. Alcidion’s main products include Miya Precision – a platform which delivers a suite of flexible modules allowing consolidation of patient information from disparate sources, and Smartpage, a secure smartphone and web-based system for hospital communication and task management which facilitates clear and secure patient handover as well as management of non-clinical patient services. A key issue underpinning Alcidion’s proposition is a significant increase in patient-related data which hospital systems grappling with legacy IT have struggled to handle. In FY22 ALC has renewed and acquired significant contracts with Australian health systems and UK NHS Trusts resulting in a 42% increase in recurring revenue</p>
<div>
<div>
<div>
<div>
<h3>Business model</h3>
<p>Alcidion’s focus on data integration, analytics and presentation allows the company’s products to be integrated with larger Electronic Medical Records (EMR) systems – adding value to hospital administration and clinical outcomes through better, timely, analysis of a patient’s treatment, test results and outcomes. Products are provided via ongoing contracted licence fees payable by the hospital, with one-off implementation fees and recurring technical service fees. Product and associated recurring revenue streams make up the majority of revenue, with technical services (including product implementation) making up the remainder. ALC serves 401 hospitals, 87 Healthcare organisations and has 65k beds using ALC technology. ALC is selling systems which are mandated in the UK for NHS facilities by legislation. ALC’s modular strategy enables hospitals to progressively add modules, allowing them to move to full digitisation of patient records, administration and clinical processes over time. This strategy is driving contract renewals, upgrades and new business.</p>
<h3>Record FY22 recurring, non-recurring and future revenue</h3>
<p>Revenue in FY22 rose 33% to $34.4m with 68% derived from recurring sources. The company starts FY23 with record contracted revenue for FY23 of $28.3m, which is 87% higher than at the same time in the previous year. FY22 cash receipts were $41.4m, and the company delivered for a net positive operating cash flow of $1.0m. The business has low ongoing capex requirements, with spend on PP&amp;E of $0.3m in FY22. Alcidion reported Q1 FY23 negative operating cashflow of $0.5m, a significant improvement from the negative $3.4m reported in Q1 FY22, following an 83% increase in cash receipts to $12.0m.</p>
<h3>Trading at a discount to tech peers</h3>
<p>Comparable ASX-listed peer companies are not direct competitors however companies like PME and 4DX are offering similar transformative IT solutions to medical facilities. Post the development of the world-wide web the health sector is moving into the second cloud-based stage of IT development. These companies are all expected to benefit and ALC trading at 3.2x sales appears underpriced given the company’s success and balance sheet strength.</p>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>





Alcidion (ASX:ALC) was founded in Adelaide in 2000 with the aim of driving meaningful change in health outcomes with smart technology and joined the ASX in January 2016. ALC aims to deliver value to existing patient and clinician information systems by aggregating the data available in healthcare systems, centralising it in the company’s Miya Precision platform, and using that data to support health professionals in their clinical decision- making. ALC has expanded organically and by acquisition into the Australian, New Zealand and UK markets with a significant step-up in the UK since acquiring MKM Health in 2018. ALC went on to acquire Silverlink in December 2021 funded by a $55m capital raising. Silverlink is a Patient Administration System (PAS) provider serving the UK NHS. Alcidion’s main products include Miya Precision – a platform which delivers a suite of flexible modules allowing consolidation of patient information from disparate sources, and Smartpage, a secure smartphone and web-based system for hospital communication and task management which facilitates clear and secure patient handover as well as management of non-clinical patient services. A key issue underpinning Alcidion’s proposition is a significant increase in patient-related data which hospital systems grappling with legacy IT have struggled to handle. In FY22 ALC has renewed and acquired significant contracts with Australian health systems and UK NHS Trusts resulting in a 42% increase in recurring revenue




Business model
Alcidion’s focus on data integration, analytics and presentation allows the company’s products to be integrated with larger Electronic Medical Records (EMR) systems – adding value to hospital administration and clinical outcomes through better, timely, analysis of a patient’s treatment, test results and outcomes. Products are provided via ongoing contracted licence fees payable by the hospital, with one-off implementation fees and recurring technical service fees. Product and associated recurring revenue streams make up the majority of revenue, with technical services (including product implementation) making up the remainder. ALC serves 401 hospitals, 87 Healthcare organisations and has 65k beds using ALC technology. ALC is selling systems which are mandated in the UK for NHS facilities by legislation. ALC’s modular strategy enables hospitals to progressively add modules, allowing them to move to full digitisation of patient records, administration and clinical processes over time. This strategy is driving contract renewals, upgrades and new business.
Record FY22 recurring, non-recurring and future revenue
Revenue in FY22 rose 33% to $34.4m with 68% derived from recurring sources. The company starts FY23 with record contracted revenue for FY23 of $28.3m, which is 87% higher than at the same time in the previous year. FY22 cash receipts were $41.4m, and the company delivered for a net positive operating cash flow of $1.0m. The business has low ongoing capex requirements, with spend on PP&amp;E of $0.3m in FY22. Alcidion reported Q1 FY23 negative operating cashflow of $0.5m, a significant improvement from the negative $3.4m reported in Q1 FY22, following an 83% increase in cash receipts to $12.0m.
Trading at a discount to tech peers
Comparable ASX-listed peer companies are not direct competitors however companies like PME and 4DX are offering similar transformative IT solutions to medical facilities. Post the development of the world-wide web the health sector is moving into the second cloud-based stage of IT development. These companies are all expected to benefit and ALC trading at 3.2x sales appears underpriced given the company’s success and balance sheet strength.









Alcidion Group Ltd - Breaking Through in the UK’s NHS

<div>
<table class="table table-striped">
<tbody>
<tr>
<td>
<div>
<p><a target="_blank"></a><a target="_blank"></a><a target="_blank"></a><a target="_blank"></a><a target="_blank"></a><a target="_blank"></a><a target="_blank"></a><a target="_blank"></a><a target="_blank"></a><a target="_blank"></a><a target="_blank">Alcidion was founded in Adelaide in 2000 with the aim of driving meaningful change in health outcomes with smart technology. ALC joined the ASX in Jan 2016 as a backdoor listing via Naracoota Resources. The company delivers patient and clinician information systems for Emergency Department, Outpatient and Inpatient management and medical records. ALC has expanded organically and by acquisition into the Australian, New Zealand and the UK markets with a significant step-up in the UK since acquiring MKM Health in 2018. The company’s main products are: Miya Precision – a platform which delivers a suite of flexible modules which allow consolidation of patient information from disparate sources, and Smartpage, a secure smartphone and web-based system for hospital communication and task management which provides clear and secure patient handover as well as management of non-clinical patient services. A key issue underpinning the business is that there has been a significant increase in patient-related data which hospital systems grappling with legacy IT have struggled to handle.</a></p>
</div>
</td>
</tr>
</tbody>
</table>
</div>







Alcidion was founded in Adelaide in 2000 with the aim of driving meaningful change in health outcomes with smart technology. ALC joined the ASX in Jan 2016 as a backdoor listing via Naracoota Resources. The company delivers patient and clinician information systems for Emergency Department, Outpatient and Inpatient management and medical records. ALC has expanded organically and by acquisition into the Australian, New Zealand and the UK markets with a significant step-up in the UK since acquiring MKM Health in 2018. The company’s main products are: Miya Precision – a platform which delivers a suite of flexible modules which allow consolidation of patient information from disparate sources, and Smartpage, a secure smartphone and web-based system for hospital communication and task management which provides clear and secure patient handover as well as management of non-clinical patient services. A key issue underpinning the business is that there has been a significant increase in patient-related data which hospital systems grappling with legacy IT have struggled to handle.







Alcidion (ALC) Breaking Through in the UK's NHS

Australia

Alcidion Group Limited provides clinical decision support solutions. The Company offers clinical informatics technology that empowers clinicians with decision support tools to ensure the highest quality of care for their patients. Alcidion Group operates in Australia and the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Alcidion (ALC AU)

Alcidion Group Ltd - Breaking Through in the UK’s NHS

Alcidion (ASX:ALC) was founded in Adelaide in 2000 with the aim of driving meaningful change in health outcomes with smart technology and...

Research as a Service (RaaS)

Alcidion (ALC) Breaking Through in the UK's NHS

Alcidion was founded in Adelaide in 2000 with the aim of driving meaningful change in health outcomes with smart technology. ALC joined the...

Research as a Service (RaaS)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)